Innate Pharma Highlights Proprietary Tetra-specific ANKET NK Cell Engager IPH6501 at the EHA 2023 Congre
Benzinga - IPH6501 is a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic, based on ANKET platform, targeting CD20 developed for the treatment of B-cell non-Hodgkin's lymphomas
- IPH6501 is progressing towards a Phase 1 clinical trial in 2023
Innate Pharma SA IPHIPHA ("Innate" or the "Company") today announced that updated preclinical data on its IPH6501 tetra-specific ANKET (Antibody-based Natural Killer cell Engager Therapeutics) are presented at the European Hematology Association (EHA) 2023 congress. IPH6501 is a first-in-class CD20-targeting tetra-specific ANKET that co-engages two activating receptors (NKp46 and CD16), the interleukin-2 receptor (without involvement of the IL-2R subunit) with a human IL-2 variant and CD20 target antigen on malignant B cells.
In preclinical settings, IPH6501 was shown to induce NK cell proliferation and to trigger high NK cell cytoxicity against CD20+ target cells in in vitro assays, in ex vivo assays with relapse/refractory (R/R) B-NHL patient samples who received at least one prior treatment, as well as in in vivo studies in non-human primates. A surrogate of IPH6501 mediated a potent anti-tumor activity in vivo in CD20+ tumor models in mice. In addition, in ex vivo assays with R/R B-NHL patient samples, IPH6501 was shown to be more efficient than a T cell engager targeting CD20.
